Antibodies to Crohn's Disease Peptide 353 As a Diagnostic Marker for Pediatric Crohn's Disease: a Prospective Multicenter Study in Japan

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2020 Jan 26

PMID 31980893

Citations 1

Authors

Tatsuki Mizuochi

Katsuhiro Arai

Takahiro Kudo

Ryusuke Nambu

Hitoshi Tajiri

Tomoki Aomatsu

Naoki Abe

Toshihiko Kakiuchi

Kunio Hashimoto

Tsuyoshi Sogo

Michiko Takahashi

Yuri Etani

Yugo Takaki

Ken-Ichiro Konishi

Jun Ishihara

Hitoshi Obara

Tatsuyuki Kakuma

Shunsuke Kurei

Yushiro Yamashita

Keiichi Mitsuyama

Affiliations

Soon will be listed here.

Abstract

Background: Various serologic markers such as anti-glycoprotein 2 antibodies and anti-Saccharomyces cerevisiae antibodies have been reported to be diagnostically useful in Crohn's disease. Mitsuyama et al. reported that antibodies to Crohn's disease peptide 353, a newly proposed serologic marker, were more useful in Japanese adults than anti-Saccharomyces. We addressed the same issue in Japanese children and adolescents.

Methods: Prospectively enrolled subjects under 17 years old assessed and treated at 12 pediatric centers in Japan included groups with Crohn's disease, ulcerative colitis, other intestinal diseases, or good health. The 3 serum markers were analyzed by enzyme-linked immunosorbent assays.

Results: Enrolled subjects, numbering 367, included 120 with Crohn's disease, 148 with ulcerative colitis, 56 with other intestinal diseases, and 43 healthy subjects. In Crohn's disease, anti-Crohn's disease peptide 353, anti-glycoprotein 2, and anti-Saccharomyces concentrations (median, 2.25, 3.0, and 8.9 U/mL) were significantly greater than in ulcerative colitis (1.1, 1.9, and 3.4; all P < 0.001), other intestinal diseases (1.1, 1.85, and 2.95; all P < 0.001), and healthy controls (1.1, 1.7, and 2.8; all P < 0.001), respectively. At 95% specificity, sensitivity of anti-Crohn's disease peptide (45.0%) was significantly higher than for anti-glycoprotein 2 (30.8%; P < 0.05) or anti-Saccharomyces (26.7%; P < 0.01).

Conclusions: Anti-Crohn's disease peptide 353 proved more useful for diagnosis of Crohn's disease in Japanese children than the other 2 markers. To our knowledge, this is the first pediatric report to that effect.

Citing Articles

Diagnostic utility, disease activity, and disease phenotype correlation of serum ASCA, pANCA, and PR3-ANCA in pediatric inflammatory bowel disease.

Kim J, Choi Y, Jung S, Yang H J Pediatr (Rio J). 2023; 100(2):204-211.

PMID: 38012956 PMC: 10943302. DOI: 10.1016/j.jped.2023.10.005.

References

Gironella M, Iovanna J, Sans M, Gil F, Penalva M, Closa D . Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut. 2005; 54(9):1244-53. PMC: 1774660. DOI: 10.1136/gut.2004.056309. View

Main J, McKenzie H, Yeaman G, Kerr M, Robson D, Pennington C . Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ. 1988; 297(6656):1105-6. PMC: 1834894. DOI: 10.1136/bmj.297.6656.1105. View

Mitsuyama K, Niwa M, Takedatsu H, Yamasaki H, Kuwaki K, Yoshioka S . Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol. 2016; 22(3):1304-10. PMC: 4716040. DOI: 10.3748/wjg.v22.i3.1304. View

Hase K, Kawano K, Nochi T, Pontes G, Fukuda S, Ebisawa M . Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature. 2009; 462(7270):226-30. DOI: 10.1038/nature08529. View

Saxon A, Shanahan F, Landers C, Ganz T, Targan S . A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990; 86(2):202-10. DOI: 10.1016/s0091-6749(05)80067-3. View

Russell R, Ip B, Aldhous M, MacDougall M, Drummond H, Arnott I . Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease. J Pediatr Gastroenterol Nutr. 2009; 48(2):161-7. DOI: 10.1097/MPG.0b013e318183e112. View

Levine A, Griffiths A, Markowitz J, Wilson D, Turner D, Russell R . Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17(6):1314-21. DOI: 10.1002/ibd.21493. View

Horn M, Peter A, Righini Grunder F, Leichtle A, Spalinger J, Schibli S . PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease. PLoS One. 2018; 13(12):e0208974. PMC: 6296712. DOI: 10.1371/journal.pone.0208974. View

Sitaraman S, Klapproth J, Moore 3rd D, Landers C, Targan S, Williams I . Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2004; 288(2):G403-6. DOI: 10.1152/ajpgi.00357.2004. View

10.

El-Matary W, Dupuis K, Sokoro A . Anti-Saccharomyces cerevisiae antibody titres correlate well with disease activity in children with Crohn's disease. Acta Paediatr. 2015; 104(8):827-30. DOI: 10.1111/apa.13026. View

11.

Mitsuyama K, Niwa M, Masuda J, Kuwaki K, Yamasaki H, Takedatsu H . Isolation and characterization of a novel short peptide associated with Crohn's disease. Clin Exp Immunol. 2011; 166(1):72-9. PMC: 3193921. DOI: 10.1111/j.1365-2249.2011.04444.x. View

12.

Mitsuyama K, Niwa M, Masuda J, Yamasaki H, Kuwaki K, Takedatsu H . Possible diagnostic role of antibodies to Crohn's disease peptide (ACP): results of a multicenter study in a Japanese cohort. J Gastroenterol. 2013; 49(4):683-91. DOI: 10.1007/s00535-013-0916-9. View

13.

Reese G, Constantinides V, Simillis C, Darzi A, Orchard T, Fazio V . Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006; 101(10):2410-22. DOI: 10.1111/j.1572-0241.2006.00840.x. View

14.

Takedatsu H, Mitsuyama K, Fukunaga S, Yoshioka S, Yamauchi R, Mori A . Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018; . DOI: 10.1111/jgh.14140. View

15.

Rober N, Noss L, Goihl A, Reinhold D, Jahn J, de Laffolie J . Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(9):1624-1636. DOI: 10.1097/MIB.0000000000001159. View

16.

Wei B, Huang T, Dalwadi H, Sutton C, Bruckner D, Braun J . Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immun. 2002; 70(12):6567-75. PMC: 133002. DOI: 10.1128/IAI.70.12.6567-6575.2002. View

17.

Landers C, Cohavy O, Misra R, Yang H, Lin Y, Braun J . Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002; 123(3):689-99. DOI: 10.1053/gast.2002.35379. View

18.

Levine A, Koletzko S, Turner D, Escher J, Cucchiara S, de Ridder L . ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2013; 58(6):795-806. DOI: 10.1097/MPG.0000000000000239. View

19.

Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Buttner T, Jungblut P . Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut. 2009; 58(12):1620-8. DOI: 10.1136/gut.2008.162495. View

20.

Ruemmele F, Targan S, Levy G, Dubinsky M, Braun J, Seidman E . Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998; 115(4):822-9. DOI: 10.1016/s0016-5085(98)70252-5. View